MedinCell S.A. (EPA: MEDCL)

Market Cap	542.19M
Revenue (ttm)	11.95M
Net Income (ttm)	-25.04M
Shares Out	29.09M
EPS (ttm)	-0.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,454
Open	18.58
Previous Close	18.48
Day's Range	18.30 - 18.64
52-Week Range	5.25 - 18.74
Beta	1.17
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 19, 2024

About MedinCell

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 134
• Stock Exchange: Euronext Paris
• Ticker Symbol: MEDCL

Financial Performance

In 2023, Groupe Guillin's revenue was 885.86 million, a decrease of -1.40% compared to the previous year's 898.47 million. Earnings were 75.43 million, an increase of 47.92%.